We are live on ! Find out more
FBLG icon

FibroBiologics
FBLG

63 hedge funds and large institutions have $11.9M invested in FibroBiologics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

3% more funds holding

Funds holding: 61 → 63 (+2)

0.08% more ownership

Funds ownership: 0.78% → 0.85% (+0.08%)

29% less capital invested

Capital invested by funds: $16.8M → $11.9M (-$4.95M)

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$377K
2
State Street
State Street
Massachusetts
+$265K
3
UBS Group
UBS Group
Switzerland
+$228K
4
Jane Street
Jane Street
New York
+$132K
5
OSAM
O'Shaughnessy Asset Management
Connecticut
+$108K

Top Sellers

Rank Fund Capital Flow
1
SF
Symphony Financial
Texas
-$75.8K
2
CFP
Cascade Financial Partners
California
-$53.7K
3
Osaic Holdings
Osaic Holdings
Arizona
-$48.5K
4
Morgan Stanley
Morgan Stanley
New York
-$35.2K
5
Millennium Management
Millennium Management
New York
-$34.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$3.57M +$79.4K +1,480 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.82M +$377K +7,015 +18%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$1.21M +$13.8K +258 +0.9%
State Street
4
State Street
Massachusetts
$1.15M +$265K +4,934 +21%
CFP
5
Cascade Financial Partners
California
$565K -$53.7K -1,000 -7%
Northern Trust
6
Northern Trust
Illinois
$431K +$13.3K +247 +2%
UBS Group
7
UBS Group
Switzerland
$256K +$228K +4,242 +196%
OAS
8
Optivise Advisory Services
Tennessee
$220K – – –
RCM
9
Requisite Capital Management
Texas
$219K – – –
Bank of America
10
Bank of America
North Carolina
$180K -$20K -373 -8%
AIFAIM
11
American Institute for Advanced Investment Management
Arizona
$176K – – –
Cerity Partners
12
Cerity Partners
New York
$156K +$69.8K +1,300 +50%
Charles Schwab
13
Charles Schwab
California
$139K – – –
Goldman Sachs
14
Goldman Sachs
New York
$129K +$61.1K +1,138 +54%
Jane Street
15
Jane Street
New York
$122K +$132K +2,461 +415%
Morgan Stanley
16
Morgan Stanley
New York
$115K -$35.2K -656 -19%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$101K – – –
Barclays
18
Barclays
United Kingdom
$86.6K +$8.96K +167 +8%
OSAM
19
O'Shaughnessy Asset Management
Connecticut
$80.8K +$108K +2,020 New
RWB
20
RMR Wealth Builders
New Jersey
$76.7K +$268 +5 +0.3%
CIA
21
Concurrent Investment Advisors
Florida
$70.6K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$69.6K -$48.5K -904 -34%
N
23
Nuveen
North Carolina
$69.1K – – –
EFL
24
ERn Financial LLC
Wisconsin
$63.6K – – –
NA
25
NewEdge Advisors
Louisiana
$51.8K – – –
1
2 3

FBLG Hedge Fund Activity: Q4 2024 in Review

63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q4 2024, worth a combined $11.9M — down 29% from $16.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new FBLG positions and 4 closed out — a net gain of 3 holders — while 23 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $377K. The largest seller was Symphony Financial, exiting entirely with an estimated $75.8K sold.

  • 63 institutional investors held FibroBiologics (FBLG) as of Q4 2024, up from 61 in Q3 2024.
  • Funds reported $11.9M of FibroBiologics stock for Q4 2024, down 29% quarter-over-quarter.
  • 7 funds opened new FibroBiologics positions in Q4 2024 and 4 closed out, a net change of +3 holders.
  • The largest FibroBiologics buyer in Q4 2024 was Vanguard Group, an estimated $377K added.
  • The largest FibroBiologics seller in Q4 2024 was Symphony Financial, an estimated $75.8K sold.

Based on aggregated 13F filings for Q4 2024.